Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT01155817 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Start date: August 2010
Phase: Phase 1
Study type: Interventional

PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.

NCT ID: NCT01153971 Completed - Clinical trials for Non-Hodgkin's Lymphoma

A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.

NCT ID: NCT01149668 Completed - Multiple Myeloma Clinical Trials

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.

NCT ID: NCT01148173 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas

Start date: October 2007
Phase: Phase 2
Study type: Interventional

Central nervous system (CNS) relapses of aggressive lymphomas are a rare but devastating complication. There is no therapy standard, conventional approaches are palliative. This study investigates an intensive chemotherapy with CNS penetrating drugs followed by high-dose chemotherapy and autologous stem cell transplantation as a potentially curative approach.

NCT ID: NCT01145495 Completed - Clinical trials for Ann Arbor Stage III Grade 2 Follicular Lymphoma

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Start date: June 15, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lenalidomide and rituximab work in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide together with rituximab may kill more cancer cells.

NCT ID: NCT01144754 Terminated - Lymphoma Clinical Trials

Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

Start date: February 2009
Phase: N/A
Study type: Observational

This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made during normal clinical practice.

NCT ID: NCT01144364 Completed - Clinical trials for Non-Hodgkin's Lymphoma

A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Start date: January 2004
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

NCT ID: NCT01135849 Completed - Breast Cancer Clinical Trials

B-Receptor Signaling in Cardiomyopathy

Start date: November 2008
Phase: N/A
Study type: Observational

We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.

NCT ID: NCT01133158 Completed - Clinical trials for Non-Hodgkin's Lymphoma

R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Start date: July 2009
Phase: Phase 2
Study type: Interventional

Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.

NCT ID: NCT01129193 Completed - Clinical trials for Recurrent Mantle Cell Lymphoma

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Start date: May 4, 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AR-42 in treating patients with advanced or relapsed multiple myeloma, chronic lymphocytic leukemia, or lymphoma.